Views
5 years ago

Treatment for Restless Legs Syndrome - AHRQ Effective Health ...

Treatment for Restless Legs Syndrome - AHRQ Effective Health ...

Treatment for Restless Legs Syndrome - AHRQ Effective Health

Comparative Effectiveness Review Number 86 Treatment for Restless Legs Syndrome

  • Page 2 and 3: Comparative Effectiveness Review Nu
  • Page 4 and 5: Preface The Agency for Healthcare R
  • Page 6 and 7: Peer Reviewers Philip M. Becker, M.
  • Page 8 and 9: children, or those with end-stage r
  • Page 10 and 11: Discussion.........................
  • Page 12 and 13: Executive Summary Introduction Rest
  • Page 14 and 15: Key Question 2. What are the harms
  • Page 16 and 17: Strength of the Body of Evidence We
  • Page 18 and 19: to 74) of randomized participants.
  • Page 20 and 21: evidence). In the maintenance trial
  • Page 22 and 23: Short-term adverse effects from tre
  • Page 24 and 25: 3.18]). 66 By 12 months, 21 of 31 s
  • Page 26 and 27: Table A. Overall strength of eviden
  • Page 28 and 29: Table C. Overall strength of eviden
  • Page 30 and 31: a dose effect for the outcomes of I
  • Page 32 and 33: Table D. Future research recommenda
  • Page 34 and 35: 14. Atkins D, Chang S, Gartlehner G
  • Page 36 and 37: 47. Bayard M, Bailey B, Acharya D,
  • Page 38 and 39: Introduction Overview Restless legs
  • Page 40 and 41: Table 1. Pharmacologic treatments f
  • Page 42 and 43: Table 2. Methods of assessment (con
  • Page 44 and 45: treatment-related harms and adheren
  • Page 46 and 47: Figure 1. Analytical framework KQ =
  • Page 48 and 49: Table 3. Inclusion criteria Domain
  • Page 50 and 51: imply that the included studies wer
  • Page 52 and 53:

    Description of Included Studies Of

  • Page 54 and 55:

    (low-strength evidence). 21 Strengt

  • Page 56 and 57:

    IRLS-Mean Change From Baseline (Fig

  • Page 58 and 59:

    enacarbil therapy were significantl

  • Page 60 and 61:

    weeks. Near-infrared light treatmen

  • Page 62 and 63:

    • One small crossover trial repor

  • Page 64 and 65:

    months to 10 years reported augment

  • Page 66 and 67:

    Table 4. Outcomes evaluated in plac

  • Page 68 and 69:

    Table 6. Overall strength of eviden

  • Page 70 and 71:

    Figure 3. Efficacy outcomes for tre

  • Page 72 and 73:

    Figure 4. Efficacy outcomes for tre

  • Page 74 and 75:

    Figure 6. Efficacy outcomes for tre

  • Page 76 and 77:

    Figure 8. Efficacy outcomes for tre

  • Page 78 and 79:

    Table 10. Overall strength of evide

  • Page 80 and 81:

    Figure 10. Efficacy outcomes for tr

  • Page 82 and 83:

    Table 11. Long-term harms with phar

  • Page 84 and 85:

    Table 12. Strength of evidence for

  • Page 86 and 87:

    Figure 13. Short-term harms of trea

  • Page 88 and 89:

    Figure 15. Short-term harms of trea

  • Page 90 and 91:

    Figure 17. Patients with ≥1 adver

  • Page 92 and 93:

    Discussion The primary intent of th

  • Page 94 and 95:

    effects suggest that for many RLS p

  • Page 96 and 97:

    Table 15. Future research recommend

  • Page 98 and 99:

    18. Lettieri CJ, Eliasson AH. Pneum

  • Page 100 and 101:

    51. Ferini-Strambi L. Restless legs

  • Page 102 and 103:

    Acronyms and Abbreviations AHRQ Age

  • Page 104 and 105:

    Appendix B. Excluded Studies 1. Bli

  • Page 106 and 107:

    40. Pieta J, Millar T, Zacharias J,

  • Page 108 and 109:

    Appendix C. Table 2. Summary of stu

  • Page 110 and 111:

    Appendix C. Table 4. Summary of stu

  • Page 112 and 113:

    Appendix D. Table 2. Individual Stu

  • Page 114 and 115:

    Study Design: crossover Duration: t

  • Page 116 and 117:

    Study Characteristics and Design ti

  • Page 118 and 119:

    Study Characteristics and Design St

  • Page 120 and 121:

    Study Characteristics and Design St

  • Page 122 and 123:

    Study Characteristics and Design St

  • Page 124 and 125:

    Study Characteristics and Design St

  • Page 126 and 127:

    Study Characteristics and Design St

  • Page 128 and 129:

    Study Characteristics and Design Ge

  • Page 130 and 131:

    Appendix E. Table 2. Evidence Table

  • Page 132 and 133:

    Study Characteristics and Design St

  • Page 134 and 135:

    Study Characteristics and Design In

  • Page 136 and 137:

    Appendix E. Table 3. Evidence Table

  • Page 138 and 139:

    Appendix E. Table 5. Evidence Table

  • Page 140 and 141:

    Study Characteristics and Design Du

  • Page 142 and 143:

    Study Characteristics and Design St

  • Page 144 and 145:

    Study Characteristics and Design pa

  • Page 146 and 147:

    Appendix F. Outcomes Tables Appendi

  • Page 148 and 149:

    Author year Kushida, 2008 8 Trenkwa

  • Page 150 and 151:

    Author year Study Duration (weeks)

  • Page 152 and 153:

    Appendix F. Table 5. International

  • Page 154 and 155:

    Appendix F. Figure 1. IRLS Remitter

  • Page 156 and 157:

    IRLS Responders (≥50% score reduc

  • Page 158 and 159:

    Patients with ≥1 serious adverse

  • Page 160 and 161:

    Application site reactions (Rotigot

  • Page 162 and 163:

    Somnolence Dopamine agonists Placeb

  • Page 164 and 165:

    Appendix. F. Figure3. Efficacy and

  • Page 166 and 167:

    Unsteadiness/dizziness Study or Sub

  • Page 168 and 169:

    Headache Study or Subgroup Events 2

  • Page 170 and 171:

    RSL-QoL Dopamine agonists Placebo S

  • Page 172 and 173:

    Vomiting Dopamine agonists Placebo

  • Page 174 and 175:

    Appendix F. Figure 5. Efficacy and

  • Page 176 and 177:

    Augmentation Study or Subgroup Tren

  • Page 178 and 179:

    Nausea Dopamine agonist Placebo Ris

  • Page 180 and 181:

    Fatigue Dopamine agonist Placebo Ri

  • Page 182 and 183:

    Appendix F. Table 10a. Self-rated q

  • Page 184 and 185:

    Appendix F. Table 13. Self-rated qu

  • Page 186 and 187:

    Appendix F. Table 14. Patient globa

  • Page 188 and 189:

    Trenkwalder, 2008 10 29 Placebo 54.

  • Page 190 and 191:

    Trenkwalder, 2008 10 96/341 (28.2)

  • Page 192 and 193:

    Appendix G. Table 3 Specific advers

  • Page 194 and 195:

    Appendix G. Table 5 Adverse effects

  • Page 196 and 197:

    Appendix G. Table 9 Specific advers

  • Page 198 and 199:

    19. Winkelman JW, Bogan RK, Schmidt

Restless Legs Syndrome: Restless Legs Syndrome
Treatment Options for Rotator Cuff Tears - AHRQ Effective Health ...
Renal Artery Stenosis Treatments - AHRQ Effective Health Care ...
Treatment Options for Rotator Cuff Tears - AHRQ Effective Health ...
Registries for Evaluating Patient Outcomes - AHRQ Effective Health ...
Therapies for Treatment- Resistant Depression - AHRQ Effective ...
Non-surgical Treatments for Urinary Incontinence - AHRQ Effective ...
Gestational Diabetes - AHRQ Effective Health Care Program ...
Gestational Diabetes - AHRQ Effective Health Care Program
Gestational Diabetes - AHRQ Effective Health Care Program ...
Treating High Cholesterol - AHRQ Effective Health Care Program
Chronic Fatigue Syndrome: diagnosis, treatment and care ... - KCE
Rheumatoid Arthritis Medicines - AHRQ Effective Health Care Program
Medicines for Type 2 Diabetes - AHRQ Effective Health Care Program
The Treatment of Restless Legs Syndrome and Periodic ... - Sleep
Dopamine agonists for restless legs syndrome - Update Software
Successful Treatment of Recalcitrant Restless Legs Syndrome With ...
Oxcarbazepine Treatment of Restless Legs Syndrome
Algorithms for the diagnosis and treatment of restless legs syndrome ...
Physostigmine for the Acute Treatment of Restless Legs Syndrome
Treatment of restless legs syndrome - The Movement Disorder Society
Restless legs syndrome - IAFP.com
Diagnosis and Management of Restless Legs Syndrome
Current Treatments for Restless Leg Syndrome - FreeCE
Sequential Compression Devices for Treatment of Restless Legs ...
Oral Ketamine: A Promising Treatment for Restless Legs Syndrome
EFNS guidelines on management of restless legs syndrome and ...
European Restless Legs Syndrome Study Group ... - Eurlssg.org
Pramipexole in the Management of Restless Legs Syndrome ... - Sleep
European Restless Legs Syndrome Study Group ... - Eurlssg.org